Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 45

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 45
---
 
 property.                                                                                         |

The use of the proceeds represents management’s estimates based on current business and economic conditions. We will retain broad discretion over the use of the net proceeds of this offering which may result in an allocation of net proceeds in differing amounts than those listed above, or in entirely new areas. The amount and timing of these proposed expenditures will depend on a number of factors, including the progress of our user acquisition efforts, and any unforeseen cash needs. As a result, you will be relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the proceeds will be used in a way that does not yield a favorable, or any, return for us. Pending application of the net proceeds as described above, we intend to invest the proceeds in investment grade interest bearing instruments or will hold the proceeds in interest bearing or non-interest-bearing bank accounts.

Management believes that the proceeds from this Primary Offering will be sufficient to satisfy our cash needs for the next six to twelve months.

<div align='center'>26

CAPITALIZATION</div>

The following table sets forth our cash and cash equivalents and capitalization as of September 30, 2024:

| ● | on                                                                                                                                   
 an actual basis; and                                                                                                                 |
| ● | On                                                                                                                                   
 a pro forma basis to give effect to the exercise as of December 31, 2024 of 2,800,000 options into 2,800,000 common shares at an     
 exercise price of $0.001 per share                                                                                                   |
| ● | On                                                                                                                                   
 a pro forma basis to give effect to the sale by us of 1,562,500 Units at the fixed public offering price of $3.20 per Unit (assuming 
 the sale of all securities offered hereby and assuming no exercise of the over-allotment option and no exercise of the IPO Warrants  
 issued in connection with this Primary Offering), after deducting estimated offering expenses payable by us as if the sale of the    
 securities had occurred on September 30, 2024.                                                                                       |

You should read this information together with our consolidated financial statements and related notes, as well as the information set forth under the headings “ Use of Proceeds” and “ Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere in this prospectus.

|                                                                                                                                                                                                                                                                                                             |     | As of September